TolDCB-29 by TrajectumPharma for Rheumatoid Arthritis: Likelihood of Approval

TolDCB-29 is under clinical development by TrajectumPharma and currently in Phase II for Rheumatoid Arthritis. According to GlobalData, Phase II drugs for Rheumatoid Arthritis have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TolDCB-29’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TolDCB-29 overview

TolDCB-29 is under development for the treatment of rheumatoid arthritis. The drug candidate is an autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70. It is a cell therapy which induces immune tolerance in rheumatoid arthritis patients.

For a complete picture of TolDCB-29’s drug-specific PTSR and LoA scores, buy the report here.